三友医疗(688085.SH)业绩快报：2025年归母净利润6328.95万元，同比增加451.85%

Group 1 - The company reported a total operating revenue of 543 million yuan for the year 2025, representing a year-on-year increase of 19.66% [1] - Research and development expenses amounted to 83.71 million yuan, accounting for 15.42% of total revenue [1] - The net profit attributable to the parent company reached 63.29 million yuan, a significant increase of 451.85% compared to the previous year [1] - The total assets of the company at the end of the reporting period were 2.377 billion yuan, an increase of 3.04% from the beginning of the period [1] - The equity attributable to the parent company was 2.105 billion yuan, reflecting a growth of 10.10% from the start of the year [1] Group 2 - The company is leveraging its innovative therapy advantages to develop new products and expand its product line, which has led to stable sales growth despite the pressures of volume-based procurement [2] - The ultrasound knife business has seen rapid growth in both sales and net profit during 2025 [2] - The international business, particularly through the subsidiary Implanet, achieved revenue of 12.47 million euros, a year-on-year increase of 32.62%, with the U.S. market showing a remarkable growth of 49.30% [2] - However, the international business is still in the early stages of sales promotion and market expansion, resulting in a loss of approximately 26 million yuan impacting the net profit attributable to the parent company [2] Group 3 - The company recognized share-based payment expenses of approximately 8.4 million yuan due to the implementation of an equity incentive plan [3] - Asset impairment losses and credit impairment losses were estimated at around 34 million yuan, affecting the net profit for 2025 [3] - The company's incubated investment in the Spring Breeze Spine Surgery Robot and related intelligent products is still in the registration and approval phase in China, the U.S., and the EU, and has not yet begun sales, contributing to ongoing losses [3]